Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

971
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
971
Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

448
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
448

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous electricity from charged total dissolved solids in wastewater using a wood-based ion-selective power generator.

Nature communications·2026
Same author

Reprogramming Acetaminophen Metabolism via Amide-to-Thioamide Modification to Prevent Drug-Induced Liver Injury.

Journal of medicinal chemistry·2026
Same author

The effectiveness of a plant-based milk with fermented brown rice on constipation symptoms via gut microbiota modulation: a double-blind randomized controlled trial.

European journal of nutrition·2026
Same author

Covalent Interaction Between High-Amylose Corn Starch and Ferulic Acid: Reshaping of the Structure.

Foods (Basel, Switzerland)·2026
Same author

Subgroup Analysis of Interval-censored Failure Time Data With Application to Alzheimer's Disease.

Statistics in medicine·2026
Same author

Clitocine suppresses TNBC progression by boosting CCRL2 to block survival signals and neutrophil-driven inflammation.

Journal of biological engineering·2026

Related Experiment Video

Updated: Apr 11, 2026

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models
02:44

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Published on: July 26, 2024

3.5K

Quantification and pharmacokinetic assessment of SB225002 in mouse: a selective non-peptide CXCR2 antagonist.

Xinran Wang1, Hongbo Miao2, Zhijun Liu1

  • 1Department of Pharmacy, Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai, P. R. China.

Bioanalysis
|April 10, 2026
PubMed
Summary

A new UHPLC-MS/MS method accurately detects SB225002, a CXCR2 antagonist, in mouse plasma. This study provides the first pharmacokinetic data for SB225002 in mice, aiding future clinical research.

Keywords:
SB225002mousepharmacokineticsplasmaultra-high performance liquid chromatography tandem mass spectrometry

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.1K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

858

Related Experiment Videos

Last Updated: Apr 11, 2026

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models
02:44

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Published on: July 26, 2024

3.5K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.1K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

858

Area of Science:

  • Pharmacology
  • Analytical Chemistry
  • Biomedical Science

Background:

  • SB225002 is a selective non-peptide antagonist targeting CXC Chemokine Receptor 2 (CXCR2).
  • Detection methods and pharmacokinetic parameters of SB225002 in mice were previously unreported.

Purpose of the Study:

  • To develop and validate a UHPLC-MS/MS method for quantifying SB225002 in mouse plasma.
  • To determine the pharmacokinetic profile of SB225002 in a mouse model.

Main Methods:

  • Sample preparation involved methanol-induced protein precipitation and centrifugation.
  • Analyte separation was performed using an Agilent ZORBAX SB-C18 column with an isocratic mobile phase (25% methanol, 75% water with 0.3% formic acid) at a flow rate of 0.3 mL/min.
  • Pharmacokinetic parameters were assessed in mice following method validation.

Main Results:

  • The UHPLC-MS/MS method exhibited linearity (20.00–4000.00 ng/mL), high recovery (96.9%–99.6%), and acceptable matrix effects (98.9%–104.6%).
  • SB225002 demonstrated good stability under various conditions.
  • Pharmacokinetic analysis revealed rapid absorption (tmax: 0.4 ± 0.1 h) and metabolism (t1/2: 3.4 ± 2.6 h) with significant inter-individual variability.

Conclusions:

  • A validated UHPLC-MS/MS method for SB225002 in mouse plasma was successfully established.
  • This study presents the first reported pharmacokinetic parameters for SB225002 in mice.
  • The findings may support further clinical investigations involving SB225002.